

# Disclosure on Transfers of Value to Patient Organizations and Related Methodology Note

## Transfers of Value to Patient Organizations

### Disclosure for 2023

Patient Organization	Country	Description of support	Amount of support (£)
International Brain Tumor Alliance	UK	Sponsorship to support the Patient Advocacy Symposium on Brain Metastases and the World Summit of Brain Tumor Patient Advocates Events	£9,521 <sup>2</sup>
Roy Castle Lung Cancer Foundation	UK	Global Lung Cancer Coalition- 2024 Corporate Membership Support	£28,804 <sup>2</sup>

### Disclosure for 2022

Patient Organization	Country	Description of support	Amount of support (£)
Roy Castle Lung Cancer Foundation	UK	Global Lung Cancer Coalition- 2022 Corporate Membership Support	£30,286 <sup>2</sup>
Roy Castle Lung Cancer Foundation	UK	Global Lung Cancer Coalition- 2023 Corporate Membership Support	£27,550 <sup>2</sup>
FOP Friends	UK	Sponsorship to support the 2022 FOP Conference and Family Gathering	£21,892 <sup>2</sup>

<sup>2</sup>Amount paid in USD and converted to GBP

## Methodology Note on Transfers of Value to Patient Organizations

### Purpose:

This methodological note accompanies the Disclosure of Transfers of Value to Patient Organisations for Regeneron UK Limited. Regeneron UK Limited (Regeneron UK) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc.

Regeneron UK will provide disclosures related to transfers of value made directly or indirectly through our accounting systems. The Patient Organization report outlines:

- a) The name of the Patient Organization which is the recipient of the support;
- b) The description of the support provided; and
- c) The transaction amount in local currency if there is a monetary value attached.

The terminology of the different types of support is consistent with the meaning of those transactions as defined in the ABPI Code.

Transfers of value made by collaboration or co-promotion partners should be included in their disclosure report.

### Definitions:

**Patient Organisation:** A UK based organisation mainly comprising of patients and/or caregivers or any user organisation such as a disability organisation, carer or relative organisation and consumer organisation that represents and/or supports the needs of patients and/or caregivers.

**Transfer of Value:** Transfer of Value (ToV) means a direct or indirect transfer of value, whether in cash, in-kind or otherwise, made in connection with the development or sale of medicines (whether or not for promotional purposes).

### Accounting:

**Tax:** ToVs will be reported as amounts paid to a recipient by Regeneron. Applicable taxes are the responsibility of the individual or entity receiving the payment.

**ToV Date:** ToVs are disclosed within the year the payment was made.

### Contacts:

**Media Enquiries:** For media enquiries, please contact [media@regeneron.com](mailto:media@regeneron.com)

**Global Transparency:** For enquiries related to this methodological note or ToV disclosure, please contact [aggspend@regeneron.com](mailto:aggspend@regeneron.com)